To investigate the efficacy and safety of photodynamic therapy (20% 5-amino-ketovalerate 630nm red light) in the treatment of cervical intraepithelial neoplasia 3(CIN 3)in women in the real world
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* CIN3, photodynamic therapy was required,
* type 1 2 transformation area, colposcopy was sufficient
* the lesion boundary was completely visible
* The ECC did not indicate high-grade lesions
Exclusion Criteria:
* coexistence or suspicion of cancer;
* TCT HSIL
* involving glands
* Porphyria patients, or suspected allergic to red and blue light.
* severe medical comorbidities；
Primary outcome measure(s)
Efficacy of the treatment — 1 month after the treatment colposcopy and biopsy will be performed one month after the treatment. Patients will be categorised as having complete remission(CR) if biopsy confirmed LSIL. If CIN 2 was found after the first course of PDT, it would be categorised as partial remission(PR). Those with the same grade were categorised as persistent disease(PD).
The proportion of CR after PDT treatment.
Trial sites (1)
Facility
City
Region
Status
Peking Unniversity Third Hospital
Beijing
China
Recruiting
More Peking University Third Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.